Brief Review of Pharmacotherapy for Pulmonary Arterial Hypertension

Authors: Chokkalingam MB and Scharf M

DOI: 10.23880/oajprs-16000108

Volume 2, Issue 1

Abstract

Pulmonary arterial hypertension affects the distal pulmonary vasculature causing intimal, medial, adventitial fibrosis, thickening and periadventitial changes leading to progressive increase in pulmonary vascular resistance and pulmonary arterial pressure [1]. Pulmonary hypertension (PH) is defined as mean pulmonary artery pressure equal to or greater than 25 mm Hg at rest.

Keywords: Cyclic guanosine monophosphate (cGMP); Obstructive sleep apnea; Calcium channel blockers

View PDF